Chemistries Drive Innovation.
At Flamingo, we understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeutic, especially for difficult to treat cancers, where many modalities have failed to succeed.
Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology
Flamingo Therapeutics (“Flamingo”) and Dynacure, announced today that the companies have signed a definitive merger agreement to combine their pipelines and expertise to create a leading oncology company.